Stay updated with breaking news from Meg Doherty. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Two newer simplified treatment options are at least as effective as current approaches, according to the results of a world-first international clinical trial into second-line HIV therapy led by the Kirby Institute at UNSW Sydney and presented today at the Conference on Retroviruses and Opportunistic Infections in Seattle.
A world-first international trial for second-line HIV therapy has shown two simplified treatments are at least as effective as standard care.
The death rate among these patients is about 15 percent, researchers reported. The virus should be added to the list of opportunistic infections seen in patients with advanced H.I.V., scientists said.
Zimbabwe's approval of the long-acting cabotegravir (CAB-LA) for use by HIV-negative people to reduce the risk of getting HIV could pave the way for effective options for HIV prevention, experts say.
Zimbabwe approves a long-acting injectable drug for use by HIV-negative people to cut the risk of acquiring HIV.